Based on our decades of research experience in protein ubiquitin and degradation, Degron team has designed and synthesized a unique molecular glue degrader (MGD) compound library from conceptual understanding of MGD properties. Degron discovers novel disease targets that can be degraded by MGDs from its library, including those “undruggable” by traditional small molecule inhibitors, via phenotypic screens and protein mass spectrum screens. Supported by established tools covering biochemical assays, cell-based assays and mouse genetics, MGD-target biology is fully validated and moved to preclinical and clinical development, to treat cancer, inflammation, metabolic and other diseases. Degron also predicts and selects potential MGD targets by analysis of its inhouse collection of chemical and target data, and directly screening its MGD library for their specific degraders.